In this issue of the JCI, Vaccaro and colleagues first identified EGFR inhibitors that increased the activity of anti-CD47 in an EGFR-driven NSCLC model (Figure 1B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.